Combidex Technology Sale Opens Door to a Revolution in Diagnostic Cancer Imaging

Combidex Technology Sale Opens Door to a Revolution in Diagnostic Cancer
Imaging

Improved cancer diagnostic imaging is one step closer to reality with the sale
of Combidex® by an American pharmaceutical company to a Dutch university that
intends to launch global trials, reports the International Strategic Cancer
Alliance. Combidex® is a nanoparticle fluid used with magnetic resonance
imaging (MRI) that can visualize cancer metastases with pinpoint accuracy in
lymph nodes as small as 2 - 3 millimeters, compared to conventional CT
imaging, which can only visualize malignant nodes that are larger than 8
millimeters.

KENNETT SQ., Pa., April 8, 2013 (GLOBE NEWSWIRE) -- via PRWEB - The exclusive
technology and development rights to Combidex® (ferumoxtran-10), a contrast
agent showing great potential in the field of diagnostic imaging, have been
sold by the U.S. pharmaceutical company AMAG Pharmaceuticals, Inc. to a Dutch
University Medical center. The new owner of the technology package is Radboud
University Nijmegan Medical Center (RUNMC), a part of Stichting Katholieke
Universiteit, a non-profit foundation in The Netherlands. Under the direction
of noted radiologist Jelle Barentsz, M.D., RUNMC will continue research and
development of Combidex®, to include global clinical trials advancing towards
regulatory application, a commercialized product and widespread patient
access.

The sale agreement was negotiated with the assistance of Örn Adalsteinsson,
Ph.D., President and CEO of the International Strategic Cancer Alliance, a
cancer research organization based in Kennett Square, PA.

Combidex® is an injectible nanoparticle fluid used in conjunction with
magnetic resonance imaging (MRI). Clinical cancer studies have demonstrated
Combidex's capability in visualizing malignant lesions in lymph nodes as small
as 2-3 millimeters. By comparison, state-of-the-art CT imaging can only
visualize malignant nodes that are larger than 8 millimeters.The potential of
Combidex technology includes earlier, more specific lymph node cancer
detection, resulting in more appropriate and effective therapy with reduced
side effects and improved patient outcomes.

The details of upcoming clinical trials will be announced later this year.

Reference: http://www.nejm.org/doi/full/10.1056/NEJMoa022749

For more information:
Terri Taylor, Press Officer, International Strategic Cancer Alliance
(412) 242-7995 (office) (412) 512-9272 (mobile)
ttaylor(at)is-canceralliance(dot)com

UMC St. Radboud, Press Department
Tel: + 31 24 3618910
umcstradboud(at)umcn(dot)nl

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit
http://www.prweb.com/releases/2013/4/prweb10600077.htm

CONTACT: International Strategic Cancer Alliance
         Terri Taylor, Press Officer
         ttaylor@is-canceralliance.com
         412-242-7995
 
Press spacebar to pause and continue. Press esc to stop.